Charles River Laboratories
1Q Revenues: $285.8 million (-2%)
1Q Earnings: $35.4 million (+80%)
Comments: Sales were down 7% in the Preclinical Services (PCS) segment to $112.5 million. Research Models and Services (RMS) segment sales were up 1% to $173.4 million. Earnings include an $11.1 million corporate tax benefit in continuing operations related to the disposition of the Phase I clinical business.